Septerna, Inc. Insider Trading

SEPN

Last 12 months

Insiders sold $68.8M and bought nothing on the open market.

8% of the selling was scheduled in advance under 10b5-1 plans. Director Rajeev M. Shah sold $63.5M on Aug 12, 67% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2025.

Net open-market

−$68.8M

0 buys · 16 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Mar 2025

Mar 7, 2025

Get an email when SEPN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 15	Elizabeth Bhatt President and COO	Sold10b5-1 plan 2 parts	4,000	$37.41 average	150K	2.2%	Form 4
Sep 1	Daniel D. Long SVP, Drug Discovery	Sold10b5-1 plan	3,333	$37.83	126K	3.3%	Form 4
Aug 12	Rajeev M. Shah Director	SoldNo plan 2 parts	1,493,000	$42.50 average	$63.5M	67%	Form 4
Aug 12	Third Rock Ventures GP VI, L.p. Large holder	Sold10b5-1 plan 2 parts	147,200	$50.27 average	$7.4M	1.5%	Form 4
Aug 11	Elizabeth Bhatt President and COO	Sold10b5-1 plan	25,000	$44.00	$1.1M	13%	Form 4
Aug 3	Daniel D. Long SVP, Drug Discovery	Sold10b5-1 plan 2 parts	3,334	$34.47 average	115K	3.3%	Form 4
Jul 15	Elizabeth Bhatt President and COO	Sold10b5-1 plan	4,000	$33.99	136K	2.2%	Form 4
Jul 1	Daniel D. Long SVP, Drug Discovery	Sold10b5-1 plan 2 parts	3,333	$34.36 average	115K	3.3%	Form 4
Jun 29	Samira Shaikhly Chief People Officer	Sold10b5-1 plan	2,178	$35.18	77K	73%	Form 4
Jun 22	Daniel D. Long SVP, Drug Discovery	Sold10b5-1 plan 2 parts	15,000	$35.51 average	533K	13%	Form 4
Jun 12	Samira Shaikhly Chief People Officer	Sold10b5-1 plan	6,250	$35.08	219K	89%	Form 4
Jun 1	Samira Shaikhly Chief People Officer	Sold10b5-1 plan 3 parts	5,935	$28.92 average	172K	88%	Form 4
May 26	Samira Shaikhly Chief People Officer	Sold10b5-1 plan	11,798	$30.06	355K	94%	Form 4
Apr 15	Elizabeth Bhatt President and COO	Sold10b5-1 plan 3 parts	4,000	$24.34 average	97K	2.2%	Form 4
Mar 2	Samira Shaikhly Chief People Officer	Sold10b5-1 plan 2 parts	70,453	$28.10 average	$1.98M	99%	Form 4
Feb 18	Elizabeth Bhatt President and COO	Sold10b5-1 plan 2 parts	4,000	$28.96 average	116K	2.2%	Form 4
Nov 10, 2025	Daniel D. Long SVP, Drug Discovery	SoldNo plan	3,501	$18.06	63K	3.6%	Form 4
Mar 7, 2025	Alan Ezekowitz Director	Bought	13,319	$6.93	92K	13%	Form 4
Mar 4, 2025 – Mar 6, 2025	Alan Ezekowitz Director	Bought 3 parts	86,681	$5.95 average	516K	498%	Form 4
Feb 25, 2025 – Feb 27, 2025	Jeffrey Finer CEO and President	Bought 3 parts	17,000	$5.71 average	97K	2.3%	Form 4
Feb 25, 2025 – Feb 27, 2025	Gil M Labrucherie Chief Financial Officer	Bought 2 parts	10,000	$5.69 average	57K	33%	Form 4
Feb 24, 2025	Third Rock Ventures GP V, LP Large holder	Bought	18,861	$6.00	113K	0.2%	Form 4
Feb 20, 2025 – Feb 21, 2025	Third Rock Ventures GP V, LP Large holder	Bought 2 parts	1,040,342	$5.93 average	$6.17M	11%	Form 4
Feb 19, 2025 – Feb 21, 2025	Gil M Labrucherie Chief Financial Officer	Bought 3 parts	30,000	$5.75 average	172K	New	Form 4

Oct 1510b5-1 plan
Elizabeth Bhatt
President and COO · sold 4,000 at avg $37.41
150K
2.2% of stake
Sep 110b5-1 plan
Daniel D. Long
SVP, Drug Discovery · sold 3,333 at $37.83
126K
3.3% of stake
Aug 12No plan
Rajeev M. Shah
Director · sold 1,493,000 at avg $42.50
$63.5M
67% of stake
Aug 1210b5-1 plan
Third Rock Ventures GP VI, L.p.
Large holder · sold 147,200 at avg $50.27
$7.4M
1.5% of stake
Aug 1110b5-1 plan
Elizabeth Bhatt
President and COO · sold 25,000 at $44.00
$1.1M
13% of stake
Aug 310b5-1 plan
Daniel D. Long
SVP, Drug Discovery · sold 3,334 at avg $34.47
115K
3.3% of stake
Jul 1510b5-1 plan
Elizabeth Bhatt
President and COO · sold 4,000 at $33.99
136K
2.2% of stake
Jul 110b5-1 plan
Daniel D. Long
SVP, Drug Discovery · sold 3,333 at avg $34.36
115K
3.3% of stake
Jun 2910b5-1 plan
Samira Shaikhly
Chief People Officer · sold 2,178 at $35.18
77K
73% of stake
Jun 2210b5-1 plan
Daniel D. Long
SVP, Drug Discovery · sold 15,000 at avg $35.51
533K
13% of stake
Jun 1210b5-1 plan
Samira Shaikhly
Chief People Officer · sold 6,250 at $35.08
219K
89% of stake
Jun 110b5-1 plan
Samira Shaikhly
Chief People Officer · sold 5,935 at avg $28.92
172K
88% of stake
May 2610b5-1 plan
Samira Shaikhly
Chief People Officer · sold 11,798 at $30.06
355K
94% of stake
Apr 1510b5-1 plan
Elizabeth Bhatt
President and COO · sold 4,000 at avg $24.34
97K
2.2% of stake
Mar 210b5-1 plan
Samira Shaikhly
Chief People Officer · sold 70,453 at avg $28.10
$1.98M
99% of stake
Feb 1810b5-1 plan
Elizabeth Bhatt
President and COO · sold 4,000 at avg $28.96
116K
2.2% of stake
Nov 10, 2025No plan
Daniel D. Long
SVP, Drug Discovery · sold 3,501 at $18.06
63K
3.6% of stake
Mar 7, 2025
Alan Ezekowitz
Director · bought 13,319 at $6.93
92K
13% of stake
Mar 4, 2025 – Mar 6, 2025
Alan Ezekowitz
Director · bought 86,681 at avg $5.95
516K
498% of stake
Feb 25, 2025 – Feb 27, 2025
Jeffrey Finer
CEO and President · bought 17,000 at avg $5.71
97K
2.3% of stake
Feb 25, 2025 – Feb 27, 2025
Gil M Labrucherie
Chief Financial Officer · bought 10,000 at avg $5.69
57K
33% of stake
Feb 24, 2025
Third Rock Ventures GP V, LP
Large holder · bought 18,861 at $6.00
113K
0.2% of stake
Feb 20, 2025 – Feb 21, 2025
Third Rock Ventures GP V, LP
Large holder · bought 1,040,342 at avg $5.93
$6.17M
11% of stake
Feb 19, 2025 – Feb 21, 2025
Gil M Labrucherie
Chief Financial Officer · bought 30,000 at avg $5.75
172K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SEPN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SEPN

CompareIntrinsic value

SPRYArs Pharmaceuticals Inc

$3.05+0.00%40

AGIOAgios Pharmaceuticals Inc.

$31.38+0.58%40

XNCRXencor Inc.

$35.01+14.28%0

ASRTAssertio Holdings Inc.

$9.09+0.28%10

SIGASiga Technologies Inc.

$3.15+1.29%20

CYTKCytokinetics, Incorporated

$63.60+2.07%10

TBPHTheravance Biopharma Inc.

No recent price82

ETONEton Pharmaceuticals Inc.

$50.72-0.45%75

Held by ETFs

SEPN is in 36 US ETFs. The largest of them, with SEPN's weight in each:

Spot a number that looks wrong? Check it in SEPN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SEPN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.